// App-Quantinova.ai

408 : Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors

Researchers

Presenter

  • Kevin Harrington

Principal Investigators

  • Eileen Parkes

  • Jared Weiss

  • Mathew Ingham

  • Andrs Cervantes

  • Emiliano Calvo

  • Matthew Riese

  • Ute Klinkhardt

  • Patricia Sikken

  • Michael Schmohl

  • Elena Garralda

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • OCDEM, University of Oxford, Oxford, UK

  • New York-Presbyterian/Columbia University Medical Center, Manhasset, NY

  • Biomedical Research Institute INCLICA, University of Valencia, Valencia, Spain

  • Centro Intengral Oncologico Clara campal, Madrid, Spain

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Vall dHebron University Hospital and Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona, Spain

Locations

  • United Kingdom

  • United States

  • Spain

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Interferon

Outcome

  • N/A

Study Design

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved